Targeting CREPT inhibits the progression of KRASG12D-driven lung adenoma in vivo.
Description
This dataset, named "Micro-CT for CreERT2+/-; TetO-KRASG12D; CREPTflox/flox", represent the Dicom files of Micro-CT used for analysis.
Files
Steps to reproduce
To evaluate the therapeutic potential and safety profile of systemic CREPT inhibition in LUAD treatment, we developed a genetically engineered mouse model (CreERT2+/-; TetO-KRASG12D; CREPTflox/flox). This model enables conditional deletion of CREPT after tumor initiation, allowing us to mimic a therapeutic intervention scenario (Figure 8A). In this model, KRASG12D expression was induced by Dox administration, inducing adenoma formation. Tumor development was monitored using micro-CT. Once tumors were formed, we induced systemic CREPT deletion by intraperitoneal injection of tamoxifen. Mice with varying initial tumor volumes were treated with tamoxifen to induce CREPT deletion..
Institutions
- Tsinghua University